Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study.

Sara BettonteMattia BertonFelix StaderManuel BattegayCatia Marzolini

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)

Morbidly obese PWH are at risk of presenting suboptimal Cmin for cabotegravir/rilpivirine after the first injection but also at steady-state particularly with the bimonthly administration. Therapeutic drug monitoring is advised to guide dosing interval adjustment.

Keyphrases

weight loss
metabolic syndrome
obese patients
bariatric surgery
type diabetes
insulin resistance
hiv infected patients
adipose tissue
case report
weight gain
ultrasound guided
skeletal muscle